checkAd

     137  0 Kommentare ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

    ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of the American College of Cardiology (JACC): Basic to Translational Science by a team of scientists led by Dr. Kevin O’Brien, Division of Cardiology, Department of Medicine, in collaboration with Dr. Rong Tian, Mitochondria and Metabolism Center, Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, Washington, USA. The clinical study was part of the ChromaDex External Research Program (CERP) and investigated the safety and tolerability of the company’s proprietary Niagen ingredient, patented nicotinamide riboside or NR, in Stage C heart failure patients with reduced ejection fraction (HFrEF), which occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Additionally, the effects of NR on white blood cells’ mitochondrial respiratory function, inflammation and whole blood nicotinamide adenine dinucleotide (NAD+) levels were assessed. The promising results from this study demonstrate that high-dose NR was safe and well-tolerated, almost doubling whole blood NAD+ levels, increasing white blood cell mitochondrial respiratory function and decreasing the expression of inflammatory markers. This study marks a major milestone as it is the first study to investigate the safety and tolerability of NR in a randomized, placebo-controlled trial of patients with heart failure, a crucial step that will pave the way for future clinical research.

    “On behalf of CERP, we are thrilled with the results of this study as it builds on the pilot study by Zhou et al., 2020, which demonstrated oral supplementation of NR in Stage D heart failure patients increased whole blood NAD+ levels,” said Dr. Andrew Shao, ChromaDex Senior Vice President of Global Scientific & Regulatory Affairs. “With almost 6.2 million adults in the US alone having been diagnosed with heart failure (cdc.gov), we are very much looking forward to working with investigators to further develop this research.”

    Heart failure is a clinical condition that is caused by structural and functional defects in the heart, which results in impaired filling or pumping of blood. There are four stages to heart disease, A, B, C and D, with Stage C patients having been diagnosed with heart failure and had or currently have symptoms of the condition. Recent research suggests that a decline in NAD+ levels may contribute to dysfunctional energy metabolism in conditions like heart failure, and increasing NAD+ levels through precursor supplementation may play a role in the progression of heart failure1 2 3. NR is the most efficient NAD+ precursor and further research is needed to understand its potential as a therapeutic option for heart failure patients.

    Seite 1 von 4




    Business Wire (engl.)
    0 Follower
    Autor folgen

    ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of the American College of Cardiology (JACC): Basic to Translational Science by a team of scientists led by Dr. …